Overview

Phase 2, Placebo-Controlled, Study Assessing the Safety and Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Patients With Elevated Eye Pressure

Status:
Completed
Trial end date:
2024-02-22
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test in patients with glaucoma and elevated pressure in the eye. The main questions it aims to answer are: • ability to lower pressure in the eye • safety in the eye and the body of patients with elevated pressure in the eye. Patients will be randomly given either: - 0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion - 1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion - Placebo Ophthalmic Emulsion Patients will be tested before starting and will have one drop of the product placed into each eye twice a day for 14 days, by the site and by the patient. At the end of the study, researchers will compare the groups to see if there is a change from before use of SBI-100 Ophthalmic Emulsion to the end of study.
Phase:
Phase 2
Details
Lead Sponsor:
Skye Bioscience, Inc.